Last reviewed · How we verify
NCT05494970: RadioT HBD
Accompaniment of Patients by Dental Assistants in the Evaluation of Oral Hygiene During and After Radiotherapy Treatment.
trial testing Accompaniment by the dental assistant. in ORL Cancer in 44 participants. Completed in 30 January 2024.
30 January 2024
Quick facts
| Lead sponsor | Institut Claudius Regaud |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 44 |
| Start date | 13 October 2022 |
| Primary completion | 30 January 2024 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Accompaniment by the dental assistant.
Conditions studied
- ORL Cancer — all drugs for ORL Cancer →
Sponsor
Institut Claudius Regaud — full company profile →
Who can join
18 and older, any sex, with ORL Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Feasibility, prospective, monocentric study aiming to evaluate the interest of a written information guide, given and explained by the dental assistant, on the improvement of the oral hygiene of patients with ORL cancer at 3 months post-radiotherapy. The study will be conducted on a population of 44 patients with ORL cancer requiring radiation treatment. Each patient will be followed during 3 months post-radiotherapy (follow-up for up to 12 months post-inclusion).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Educational Interventions in Oral Hygiene for Patients Undergoing Head and Neck Cancer Radiotherapy: A Feasibility Study.
Betancourt S, Cavillon A, Teulières MC, Cabarrou B, et al · · 2026 · PMID 42209855 · DOI 10.1007/s13187-026-02849-6
Verify or expand the search:
- PubMed search for NCT05494970
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut Claudius Regaud trials
Trials by the same sponsor.
- NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
- NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
- NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
- NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
- NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05494970 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05494970.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing